Roche reports a strong start in 2019 and raises the outlook for the full-year

Group sales increase 8% at constant exchange rates and 9% in Swiss francs Pharmaceuticals Division sales up 10%, driven mainly by Ocrevus, Perjeta, Hemlibra and Tecentriq Diagnostics Division sales grow 1%, with Molecular Diagnostics as main contributor
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news